Overview An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients With Chronic Stroke Status: Recruiting Trial end date: 2021-10-31 Target enrollment: Participant gender: Summary The primary objective of this study is to evaluate the efficacy for subjects with chronic stroke after GXNPC-1 injection. Phase: Phase 2 Details Lead Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.